Valentin Goede, MD, from the University Hospital Cologne and the German CLL Study Group, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab (Gazyva; formally GA101) plus chlorambucil in patients with chronic lymphocytic leukemia (CLL) with comorbidities.

In stage 2 of the phase III CLL11 trial, patients were randomized to receive either obinutuzumab plus chlorambucil (n = 333) or rituximab plus chlorambucil (n = 330). The primary endpoint of the study was progression-free survival (PFS).

In the study, the median PFS for the obinutuzumab combination was 26.7 months compared with 15.2 months with rituximab (HR = 0.39; 

< .0001). This dramatic difference in PFS indicates that obinutuzumab is superior to rituximab in this setting, Goede notes.

In addition to PFS, impressive efficacy findings were demonstrated for the combination of chlorambucil and obinutuzumab for other endpoints, Goede indicates. Overall, 21% of patients compared to 7% experienced a complete response, for obinutuzumab and rituximab, respectively. Also, Goede suggests, the number of patients testing MRD-negative in the obinutuzumab arm was 10-fold greater than in the rituximab arm, indicating a huge difference between the two treatments.

View more from the 2013 ASH Annual Meeting

Videos

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

The CLL11 trial evaluated obinutuzumab (GA101) plus chlorambucil or rituximab plus chlorambucil versus chlorambucil alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities.

Researchers found that the combination of obinutuzumab and chlorambucil prolonged progression-free survival significantly compared with chlorambucil alone. The most important piece of this finding, Goede notes, is the hazard ratio (0.14), which signifies an 86% reduction in risk of progressing with CLL in these patients. The trial also found that the hazard ratio for rituximab and chlorambucil compared with chlorambucil alone was 0.32.

Goede says that obinutuzumab and rituximab cannot be compared head-to-head with this data alone.

View more from the 2013 ASCO Annual Meeting

Valentin Goede, MD

Articles

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

Dr. Goede on the Results from the Phase III CLL11 Trial